Table S1. Clinical characteristics of study cohort

Characteristic	n (%)	P^a
Patients, n	458	
Age at diagnosis		0.303
Median, y (IQR)	66 (61-70)	
≤65	211 (46.1)	
>65	247 (53.9)	
PSA at diagnosis		0.001
Median, ng/mL (IQR)	11.1 (7.1-17.5)	
≤6	74 (16.9)	
>6	365 (83.1)	
Pathologic Gleason score, n (%)		0.001
<6	41 (9.1)	
≥6	412 (90.9)	
Pathologic stage, n (%)		<0.001
T1/T2/T3	422 (93.6)	
T4/N1	29 (6.4)	
Recurrence	184 (40.2)	
Median follow-up time[b], mo (95% CI)	54 (50-58)	

Abbreviations: IQR, interquartile range; PSA, prostate-specific antigen; CI, confidence interval.

[a]*P* value was calculated by the log-rank test for recurrence.

[b]Median follow-up time and 95% CIs were estimated with the reverse Kaplan-Meier method.